Systemic sclerosis, or scleroderma that impacts the skin and internal organs, is one of the rarest autoimmune diseases, affecting over 80,000 people in the United States. Researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases. Dinesh Khanna M.B.B.S., M.Sc., director of the Michigan Medicine Scleroderma Program, discusses any clinical benefits of tofacitinib to patients and how the drug can work in the future.
